Decitabine salvage for TP53-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy

Haematologica. 2022 Jul 1;107(7):1709-1713. doi: 10.3324/haematol.2021.280153.

Authors

Francesca Ferraro¹, Agata Gruszczynska¹, Marianna B Ruzinova², Christopher A Miller¹, Mary Elizabeth Percival³, Geoffrey L Uy¹, Iskra Pusic¹, Meagan A Jacoby¹, Mathew J Christopher¹, Miriam Y Kim¹, Peter Westervelt¹, Amanda F Cashen¹, Mark A Schroeder¹, John F DiPersio¹, Camille N Abboud¹, Lukas D Wartman¹, Feng Gao⁴, Daniel C Link¹, Timothy J Ley¹, John S Welch¹

Affiliations

¹ Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110.
² Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110.
³ Department of Internal Medicine, Division of Hematology, University of Washington School of Medicine, Seattle, Washington 98195; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109.
⁴ Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, Missouri 63110.

No abstract available

MeSH terms

Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols
Decitabine / therapeutic use
Humans
Induction Chemotherapy
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Remission Induction
Salvage Therapy
Treatment Outcome
Tumor Suppressor Protein p53 / genetics

Substances

Antineoplastic Agents
TP53 protein, human
Tumor Suppressor Protein p53
Decitabine

Grants and funding